This is a preview of subscription content, log in via an institution to check access.
References
Biogen Idec, Fumapharm AG. Patients Show Improvement in Phase II Psoriasis Study of Novel Oral Immunomodulator. Media Release: 29 Apr 2004. Available from URL: http://www.biogen.com
Biogen Inc. Biogen Licenses Oral Psoriasis Therapy From Fumapharm AG. Media Release: 1 Oct 2003. Available from URL: http://www.biogen.com
Biogen Idec. BG-12 Psoriasis Study Meets Primary Endpoint; Oral Compound Also Being Studied for MS in Phase II Trial. Media Release: 7 Apr 2005. Available from URL: http://www.biogenidec.com
Langner A, Spellman MC. Results of a phase 2 dose-ranging and safety extension study of a novel oral fumarate, BG-12, in patients with severe psoriasis. Journal of the American Academy of Dermatology 52 (Abstr. Suppl.): 193 (plus poster) abstr. P2787, No. 3, Mar 2005
Mrowietz U, Spellman MC. Efficacy and safety of a novel formulation of an oral fumarate, BG-12, in patients with moderate to severe plaque psoriasis: results of a phase III study. Journal of the American Academy of Dermatology 52 (Abstr. Suppl.): 182 (plus poster) abstr. P2743, No. 3, Mar 2005
Rights and permissions
About this article
Cite this article
BG 12. Drugs R D 6, 229–230 (2005). https://doi.org/10.2165/00126839-200506040-00005
Published:
Issue Date:
DOI: https://doi.org/10.2165/00126839-200506040-00005